ResMed CFO Brett Sandercock retires; Aaron Bloomer appointed successor

RESMED INC

Brett Sandercock retires as CFO effective May 4, 2026; remains special advisor to CEO through Dec 2027.
Aaron Bloomer appointed CFO effective May 4; previously CFO of Exact Sciences (recently acquired by Abbott).
Bloomer compensation: $725k salary, $150k sign-on bonus, $3.3M equity grant (RSUs/PSUs with TSR metrics).
Resmed reiterates FY2026 guidance: gross margin 62-63%, SG&A 19-20%, R&D 6-7%, tax rate 21-23%.
Sandercock's retirement not due to any disagreement; retains salary, benefits and equity vesting through 2027.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Aaron Bloomer

Chief Financial Officer

RMD · RESMED INC

Effective: 2026-05-04
Filed: April 30, 2026, 7:59 PM ET

On April 30, 2026, the Company also announced it appointed Aaron Bloomer, age 40, as Chief Financial Officer, effective May 4, 2026.

Departed

Brett Sandercock

Chief Financial Officer

RMD · RESMED INC

Effective: 2026-05-04
Successor: Aaron Bloomer
Filed: April 30, 2026, 7:59 PM ET

On April 30, 2026, ResMed Inc. (the “Company”) announced that Brett Sandercock, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, will retire from his role as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Aaron Bloomer was appointed as Chief Financial Officer at RESMED INC.

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On April 30, 2026, the Company also announced it appointed Aaron Bloomer, age 40, as Chief Financial Officer, effective May 4, 2026.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Brett Sandercock departed as Chief Financial Officer at RESMED INC.

Action: retire
Role: Chief Financial Officer

Exact text from the filing

On April 30, 2026, ResMed Inc. (the “Company”) announced that Brett Sandercock, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, will retire from his role as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer.

View on SEC.gov

RESMED INC filing history →

Source: SEC EDGAR

accession 0001193125-26-197282

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.